标题
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
作者
关键词
-
出版物
Viruses-Basel
Volume 7, Issue 11, Pages 5889-5901
出版商
MDPI AG
发表日期
2015-11-16
DOI
10.3390/v7112914
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses
- (2016) Karishma Rajani et al. MOLECULAR THERAPY
- Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
- (2015) J. J. Rojas et al. CLINICAL CANCER RESEARCH
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling
- (2015) Julia V. Cockle et al. NEURO-ONCOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- T cell exhaustion during persistent viral infections
- (2015) Shannon M. Kahan et al. VIROLOGY
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- Immune modulation for cancer therapy
- (2014) J Naidoo et al. BRITISH JOURNAL OF CANCER
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity
- (2014) Fiona Errington et al. JOURNAL OF IMMUNOLOGY
- CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
- (2014) Christine E Engeland et al. MOLECULAR THERAPY
- The Profile of Tumor Antigens Which Can be Targeted by Immunotherapy Depends Upon the Tumor's Anatomical Site
- (2014) Vanesa Alonso-Camino et al. MOLECULAR THERAPY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
- (2014) D. Zamarin et al. Science Translational Medicine
- Oncolytic Poxviruses
- (2014) Winnie M. Chan et al. Annual Review of Virology
- Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
- (2014) Zong Sheng Guo et al. Frontiers in Oncology
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
- (2013) Joanne Y. H. Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
- (2013) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
- (2012) P. Msaouel et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
- (2012) Dmitriy Zamarin et al. Future Microbiology
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma
- (2012) Evanthia Galanis et al. MOLECULAR THERAPY
- Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
- (2012) Jose Pulido et al. NATURE BIOTECHNOLOGY
- Oncolytic virotherapy
- (2012) Stephen J Russell et al. NATURE BIOTECHNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- (2012) J. M. Taube et al. Science Translational Medicine
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Type I interferon is selectively required by dendritic cells for immune rejection of tumors
- (2011) Mark S. Diamond et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors
- (2011) Timothy Kottke et al. NATURE MEDICINE
- Pattern Recognition Receptors and the Innate Immune Response to Viral Infection
- (2011) Mikayla R. Thompson et al. Viruses-Basel
- Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis
- (2010) G. Schiavoni et al. CANCER RESEARCH
- REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer
- (2010) C. Comins et al. CLINICAL CANCER RESEARCH
- The PD-1 pathway in tolerance and autoimmunity
- (2010) Loise M. Francisco et al. IMMUNOLOGICAL REVIEWS
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- “Armed” oncolytic herpes simplex viruses for brain tumor therapy
- (2010) Tomoki Todo Cell Adhesion & Migration
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication
- (2009) R. J. Prestwich et al. CLINICAL CANCER RESEARCH
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma
- (2009) Neil N. Senzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors
- (2008) Y Gao et al. CANCER GENE THERAPY
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More